Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02222545




Registration number
NCT02222545
Ethics application status
Date submitted
18/08/2014
Date registered
21/08/2014
Date last updated
28/08/2024

Titles & IDs
Public title
Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies
Scientific title
A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies
Secondary ID [1] 0 0
2014-001032-11
Secondary ID [2] 0 0
OMS721-TMA-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Thrombotic Microangiopathies 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Experimental: OMS721 low dose - Administration of OMS721 at a low dose

Experimental: OMS721 medium dose - Administration of OMS721 at a medium dose

Experimental: OMS721 high dose - Administration of OMS721 at a high dose
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Assess the Safety and Tolerability of Multiple-dose Administration of OMS721 in Participants With TMA
Timepoint [1] 0 0
Day 1 to 37 days after end of treatment, approximately up to 31 weeks.
Primary outcome [2] 0 0
Number of Participants With HSCT-TMA Who Respond to OMS721
Timepoint [2] 0 0
Day 1 to up to 2 years following the first dose of OMS721
Secondary outcome [1] 0 0
Participants With HSCT-TMA Treated With OMS721: 100-day Survival
Timepoint [1] 0 0
Study Day of HSCT-TMA diagnosis to 100 days later
Secondary outcome [2] 0 0
Participants With HSCT-TMA Treated With OMS721: Overall Survival
Timepoint [2] 0 0
Study Day of HSCT-TMA diagnosis to up to 2 years following first dose of OMS721
Secondary outcome [3] 0 0
Participants With HSCT-TMA Treated With OMS721: Duration of Response
Timepoint [3] 0 0
Study Day 1 to up to 2 years following first dose of OMS721
Secondary outcome [4] 0 0
Participants With HSCT-TMA Treated With OMS721: Freedom From Platelet Transfusion
Timepoint [4] 0 0
Study Day -14 to 4 weeks following the last platelet transfusion
Secondary outcome [5] 0 0
Participants With HSCT-TMA Treated With OMS721: Freedom From Red Blood Cell (RBC) Transfusion
Timepoint [5] 0 0
Study Day -14 to 4 weeks following the last RBC transfusion
Secondary outcome [6] 0 0
Participants With HSCT-TMA Treated With OMS721: Change From Baseline in Platelet Count
Timepoint [6] 0 0
Study Day 1 to Day 97, approximately 13 weeks
Secondary outcome [7] 0 0
Participants With HSCT-TMA: Pharmacokinetics (PK) of Multiple-dose Administration of OMS721
Timepoint [7] 0 0
Pre-dose and up to 204 days post-dose
Secondary outcome [8] 0 0
Participants With HSCT-TMA (ADA)
Timepoint [8] 0 0
Pre-dose and up to 204 days post-dose
Secondary outcome [9] 0 0
Participants With HSCT-TMA Treated With OMS721: Change From Baseline in LDH
Timepoint [9] 0 0
Study Day 1 to Day 97, approximately 13 weeks
Secondary outcome [10] 0 0
Participants With HSCT-TMA Treated With OMS721: Change From Baseline in Creatine
Timepoint [10] 0 0
Study Day 1 to Day 97, approximately 13 weeks
Secondary outcome [11] 0 0
Participants With HSCT-TMA Treated With OMS721: Change From Baseline in Haptoglobin
Timepoint [11] 0 0
Study Day 1 to Day 97, approximately 13 weeks
Secondary outcome [12] 0 0
Participants With HSCT-TMA Treated With OMS721: Change From Baseline in Hemoglobin
Timepoint [12] 0 0
Study Day 1 to Day 97, approximately 13 weeks
Secondary outcome [13] 0 0
Participants With HSCT-TMA: Pharmacokinetics (PK) of Multiple-dose Administration of OMS721
Timepoint [13] 0 0
Pre-dose and up to 204 days post-dose
Secondary outcome [14] 0 0
Participants With HSCT-TMA: Pharmacokinetics (PK) of Multiple-dose Administration of OMS721
Timepoint [14] 0 0
Pre-dose and up to 204 days post-dose
Secondary outcome [15] 0 0
Participants With HSCT-TMA: Pharmacodynamics (PD)
Timepoint [15] 0 0
Pre-dose and up to 204 days post-dose

Eligibility
Key inclusion criteria
1. Are at least age 18 at screening (Visit 1)
2. Have a diagnosis of primary aHUS, persistent HSCT-associated TMA or TTP
3. No clinically apparent alternative explanation for thrombocytopenia and anemia
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Had eculizumab therapy within three months prior to screening
2. Have STEC-HUS
3. Have a positive direct Coombs test
4. Have an active systemic bacterial or fungal infection requiring antimicrobial therapy (prophylactic antimicrobial therapy administered as standard of care is allowed)

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/11/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
11/08/2020
Sample size
Target
Accrual to date
Final
58
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Minnesota
Country [3] 0 0
United States of America
State/province [3] 0 0
New York
Country [4] 0 0
United States of America
State/province [4] 0 0
North Carolina
Country [5] 0 0
United States of America
State/province [5] 0 0
Wisconsin
Country [6] 0 0
Belgium
State/province [6] 0 0
Brussels
Country [7] 0 0
Belgium
State/province [7] 0 0
Leuven
Country [8] 0 0
Belgium
State/province [8] 0 0
Liege
Country [9] 0 0
Bulgaria
State/province [9] 0 0
Sofia
Country [10] 0 0
Hong Kong
State/province [10] 0 0
Sha Tin
Country [11] 0 0
Italy
State/province [11] 0 0
Bergamo
Country [12] 0 0
Lithuania
State/province [12] 0 0
Vilnius
Country [13] 0 0
Malaysia
State/province [13] 0 0
Selangan
Country [14] 0 0
New Zealand
State/province [14] 0 0
Christchurch
Country [15] 0 0
Poland
State/province [15] 0 0
Katowice
Country [16] 0 0
Poland
State/province [16] 0 0
Krakow
Country [17] 0 0
Poland
State/province [17] 0 0
Warsaw
Country [18] 0 0
Poland
State/province [18] 0 0
Lódz
Country [19] 0 0
Singapore
State/province [19] 0 0
Singapore
Country [20] 0 0
Taiwan
State/province [20] 0 0
Taichung
Country [21] 0 0
Taiwan
State/province [21] 0 0
Taipei
Country [22] 0 0
Thailand
State/province [22] 0 0
Ban Pathumwan
Country [23] 0 0
Thailand
State/province [23] 0 0
Bangkok
Country [24] 0 0
Thailand
State/province [24] 0 0
Pathum Thani

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Omeros Corporation
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of OMS721 in patients with thrombotic microangiopathies (TMA).
Trial website
https://clinicaltrials.gov/study/NCT02222545
Trial related presentations / publications
Khaled SK, Claes K, Goh YT, Kwong YL, Leung N, Mendrek W, Nakamura R, Sathar J, Ng E, Nangia N, Whitaker S, Rambaldi A; OMS721-TMA-001 Study Group Members. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. J Clin Oncol. 2022 Aug 1;40(22):2447-2457. doi: 10.1200/JCO.21.02389. Epub 2022 Apr 19.
Pugh D, O'Sullivan ED, Duthie FA, Masson P, Kavanagh D. Interventions for atypical haemolytic uraemic syndrome. Cochrane Database Syst Rev. 2021 Mar 23;3(3):CD012862. doi: 10.1002/14651858.CD012862.pub2.
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02222545